SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

CGuard Prime

NSPR·InspireMD Inc.
MIXED
Drug Impact Rating5/10
Trial phase
Approved (FDA PMA)
Time to market
CGuard Prime is already FDA-approved and was commercially launched for CAS procedures before the May 2026 recall paused U.S. sales. The new TCAR indication was approved November 12, 2026, and the company plans a U.S. commercial relaunch in Q4 2026 pending FDA approval of the 80cm delivery system.
Why 5/10
The next hard catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (within weeks). This is an incremental commercial expansion on an already-approved platform, not a make-or-break binary. The main binary event (TCAR approval) occurred on Nov 12, 2026 and is past.
Actionable Insight MIXED

The next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.

Price Chart

Loading chart...

Executive Summary

CGuard Prime is InspireMD's mesh-covered carotid stent system for preventing stroke by treating narrowed carotid arteries. The device was already FDA-approved for CAS (transfemoral carotid artery stenting) but faced a voluntary recall of its 135cm delivery system in May 2026, pausing U.S. commercialization. On November 12, 2026, the FDA approved CGuard Prime for TCAR (transcarotid artery revascularization) procedures, doubling the U.S. addressable market to ~75,000 annual procedures. The approval was supported by the CGUARDIANS II trial showing 100% acute device success with zero adverse events at 30 days. However, the company simultaneously reported Q3 revenue of $2.24M (down 11% YoY), cash burn from $54.2M to $19.2M, and priced a heavily dilutive $37.5M public offering. The stock trades at ~$0.64 with a ~$36M market cap.

How It Works

CGuard Prime is a mesh-covered metal stent (a small tube) that is implanted into the carotid artery in the neck to prop it open and prevent stroke. The unique mesh covering is designed to trap dangerous debris (plaque and clots) against the artery wall during and after the procedure, reducing the risk of debris traveling to the brain and causing a stroke. It is used in two types of procedures: CAS (carotid artery stenting, threaded through a blood vessel from the groin) and the newer TCAR (transcarotid artery revascularization, where the stent is delivered through a small incision in the neck with temporary blood flow reversal for added protection).

Trial Status

CGuard Prime received FDA premarket approval (PMA) for CAS procedures prior to 2026. A PMA supplement for TCAR was approved November 12, 2026, supported by the CGUARDIANS II pivotal trial (50 patients, 100% acute device success, zero adverse events at 30 days). The CGUARDIANS III study of the SwitchGuard neuroprotection system with the CGuard Prime 80cm stent platform has an FDA-approved IDE. The 80cm delivery system PMA supplement is under FDA review, anticipated in Q4 2026.

The Two-Sided Case

▲ Bull Case5
FDA approved CGuard Prime for TCAR procedures on Nov 12, 2026, doubling the U.S. addressable market to ~75,000 annual carotid stenting procedures (adding 35,000+ TCAR procedures).
The CGUARDIANS II pivotal trial supporting the TCAR approval reported 100% acute device success and zero adverse events at 30 days, a strong safety/efficacy profile.
Analyst consensus is bullish: 8 Buy/Strong Buy vs 1 Hold (0 Sell) as of Nov 2026, with a mean price target of $3.33 (versus the current ~$0.64 stock price).
The company appointed Kathleen Kennedy as SVP of global sales and marketing to manage the U.S. TCAR launch, signaling commercial readiness.
The $37.5M offering provides capital to fund the U.S. TCAR commercial relaunch, R&D, and working capital through the launch phase.
▼ Bear Case5
Voluntary recall of the CGuard Prime 135cm delivery system in May 2026 paused U.S. commercialization and forced a 2026 revenue guidance withdrawal, raising questions about manufacturing/quality execution.
The $37.5M public offering priced on Nov 13, 2026 is heavily dilutive: 7.34M shares plus pre-funded warrants for 50.35M shares and common warrants for 43.27M shares, pressuring the stock (down ~17% today to $0.64).
Cash burned quickly: $19.2M at Q3 2026 vs $54.2M at year-end 2025, and the company has a history of losses and a going-concern risk.
Q3 2026 revenue of $2.24M fell 11% YoY due to the recall impact, and the company has not resumed U.S. CAS commercial sales.
The 80cm delivery system FDA approval is still pending (anticipated Q4 2026) and could be delayed, further pushing out the U.S. relaunch timeline.

Upcoming Catalysts

  • FDA decision on CGuard Prime 80cm delivery system PMA supplement (anticipated Q4 2026)
  • Planned PMA supplement submission for enhanced CGuard Prime for CAS procedures (December 2026)
  • U.S. commercial relaunch of CGuard Prime for TCAR procedures (Q4 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

InspireMD Inc. Press Release NSPR ·Originating report

Sources · 10

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 rttnews.com5 evtoday.com6 marketscreener.com7 morningstar.com8 msn.com9 pulse2.com10 globenewswire.com